Drug Type Small molecule drug |
Synonyms Afacifenacin, NS-986, SMP-986 |
Target |
Mechanism ENaC modulators(Epithelial sodium channel modulators), mAChRs antagonists(Muscarinic acetylcholine receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H30F3N3O6 |
InChIKeyKOUDXPQOXCFHHV-RHWBLDFMSA-N |
CAS Registry877614-61-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Overactive bladder syndrome | Phase 2 | US | 01 Dec 2006 | |
Overactive bladder syndrome | Phase 2 | US | 01 Dec 2006 | |
Overactive bladder syndrome | Phase 2 | EE | 01 Dec 2006 | |
Overactive bladder syndrome | Phase 2 | EE | 01 Dec 2006 | |
Overactive bladder syndrome | Phase 2 | FR | 01 Dec 2006 | |
Overactive bladder syndrome | Phase 2 | FR | 01 Dec 2006 | |
Overactive bladder syndrome | Phase 2 | DE | 01 Dec 2006 | |
Overactive bladder syndrome | Phase 2 | DE | 01 Dec 2006 | |
Overactive bladder syndrome | Phase 2 | LV | 01 Dec 2006 | |
Overactive bladder syndrome | Phase 2 | LV | 01 Dec 2006 |
Phase 2 | 550 | Placebo (Placebo) | nmdlsgymmw(aziwwstboj) = wtybhonqnm eqfxamittg (wepxxlrwsb, ihzujubvlz - loleyvttkp) View more | - | 10 Dec 2014 | ||
(20mg Dose of SMP-986) | nmdlsgymmw(aziwwstboj) = vtzomaquqa eqfxamittg (wepxxlrwsb, vljgzuydoa - tnfvrtqkmp) View more |